Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 497

1.

Is substance P a nasal epithelial neuropeptide?

Douglas SD, Leeman SE.

J Allergy Clin Immunol. 2018 Nov;142(5):1677. doi: 10.1016/j.jaci.2018.05.034. Epub 2018 Jun 27. No abstract available.

PMID:
29958676
2.

Truncation of neurokinin-1 receptor-Negative regulation of substance P signaling.

Spitsin S, Pappa V, Douglas SD.

J Leukoc Biol. 2018 Jan 10. doi: 10.1002/JLB.3MIR0817-348R. [Epub ahead of print] Review.

PMID:
29345372
3.

Editorial: Gateway to monocyte entry into the brain: CXCR7, the new orchestra conductor.

Douglas SD, Spitsin S.

J Leukoc Biol. 2017 Nov;102(5):1155-1157. doi: 10.1189/jlb.3CE0717-273R. No abstract available.

4.

The Legacy of CVI.

Pasetti MF, Douglas SD, Plaeger SF.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00276-17. doi: 10.1128/CVI.00276-17. Print 2017 Dec.

5.

Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.

Spitsin S, Tebas P, Barrett JS, Pappa V, Kim D, Taylor D, Evans DL, Douglas SD.

JCI Insight. 2017 Oct 5;2(19). pii: 95893. doi: 10.1172/jci.insight.95893.

6.

Substance P-mediated chemokine production promotes monocyte migration.

Spitsin S, Meshki J, Winters A, Tuluc F, Benton TD, Douglas SD.

J Leukoc Biol. 2017 Apr;101(4):967-973. doi: 10.1189/jlb.1AB0416-188RR. Epub 2016 Oct 21.

7.

Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.

Tuluc F, Spitsin S, Tustin NB, Murray JB, Tustin R 3rd, Schankel LA, Wiznia A, Nachman S, Douglas SD.

AIDS Res Hum Retroviruses. 2017 Feb;33(2):133-142. doi: 10.1089/AID.2016.0108. Epub 2016 Oct 18.

8.

Substance P and sickle cell disease-a marker for pain and novel therapeutic approaches.

Douglas SD.

Br J Haematol. 2016 Oct;175(2):187-188. doi: 10.1111/bjh.14299. Epub 2016 Aug 19. No abstract available.

9.

The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth.

McGuire JL, Gill AJ, Douglas SD, Kolson DL; CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group.

J Neurovirol. 2016 Dec;22(6):823-830. Epub 2016 Jun 6.

10.

Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.

Barrett JS, Spitsin S, Moorthy G, Barrett K, Baker K, Lackner A, Tulic F, Winters A, Evans DL, Douglas SD.

J Transl Med. 2016 May 26;14(1):148. doi: 10.1186/s12967-016-0904-y.

11.

The Selective Serotonin Reuptake Inhibitor Citalopram Decreases Human Immunodeficiency Virus Receptor and Coreceptor Expression in Immune Cells.

Greeson JM, Gettes DR, Spitsin S, Dubé B, Benton TD, Lynch KG, Douglas SD, Evans DL.

Biol Psychiatry. 2016 Jul 1;80(1):33-9. doi: 10.1016/j.biopsych.2015.11.003. Epub 2015 Nov 10.

12.

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, Wagner W, Winters A, Kim D, Catalano R, Evans DL, Douglas SD.

AIDS. 2015 May 15;29(8):931-9. doi: 10.1097/QAD.0000000000000638.

13.

Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.

McGuire JL, Gill AJ, Douglas SD, Kolson DL; CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group.

J Neurovirol. 2015 Aug;21(4):439-48. doi: 10.1007/s13365-015-0333-3. Epub 2015 Mar 17.

14.

Adjuvant therapies for HIV-associated neurocognitive disorders.

McGuire JL, Barrett JS, Vezina HE, Spitsin S, Douglas SD.

Ann Clin Transl Neurol. 2014 Nov;1(11):938-52. doi: 10.1002/acn3.131. Epub 2014 Oct 23. Review.

15.

Immune markers predictive of neuropsychiatric symptoms in HIV-infected youth.

McGuire JL, Kempen JH, Localio R, Ellenberg JH, Douglas SD.

Clin Vaccine Immunol. 2015 Jan;22(1):27-36. doi: 10.1128/CVI.00463-14. Epub 2014 Oct 29.

16.

Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.

Barrett JS, Bajaj G, McGuire J, Wu D, Spitsin S, Moorthy G, Zhao X, Tebas P, Evans DL, Douglas SD.

Curr HIV Res. 2014;12(2):121-31.

PMID:
24862330
17.

HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance P.

Tuluc F, Meshki J, Spitsin S, Douglas SD.

J Leukoc Biol. 2014 Jul;96(1):143-50. doi: 10.1189/jlb.4AB0813-434RR. Epub 2014 Feb 27.

18.

PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?

Barrett JS, McGuire J, Vezina H, Spitsin S, Douglas SD.

J Clin Psychopharmacol. 2013 Dec;33(6):725-8. doi: 10.1097/JCP.0b013e3182a88654.

PMID:
24100788
19.

Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.

Spitsin S, Tuluc F, Meshki J, Ping Lai J, Tustin Iii R, Douglas SD.

Neuroimmunomodulation. 2013;20(5):247-55. doi: 10.1159/000350468. Epub 2013 Jul 5.

20.

Expression of substance P, neurokinin-1 receptor and immune markers in the brains of individuals with HIV-associated neuropathology.

Spitsin S, Stevens KE, Douglas SD.

J Neurol Sci. 2013 Nov 15;334(1-2):18-23. doi: 10.1016/j.jns.2013.07.008. Epub 2013 Aug 2.

21.

Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor.

Schwartz L, Spitsin SV, Meshki J, Tuluc F, Douglas SD, Wolfe JH.

J Neurovirol. 2013 Jun;19(3):219-27. doi: 10.1007/s13365-013-0166-x. Epub 2013 Jun 14.

22.

The glucocorticoid antagonist RU-486 suppresses HIV infectivity and replication.

Benton TD, Lynch KG, Dubé B, Gettes DR, Tustin NB, Metzger DS, Blume J, Douglas SD, Evans DL.

J Neuropsychiatry Clin Neurosci. 2013 Winter;25(1):51-7. doi: 10.1176/appi.neuropsych.12060147.

PMID:
23487193
23.

Neurokinin 1 receptor mediates membrane blebbing and sheer stress-induced microparticle formation in HEK293 cells.

Chen P, Douglas SD, Meshki J, Tuluc F.

PLoS One. 2012;7(9):e45322. Epub 2012 Sep 14.

24.

Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy.

Spitsin S, Tustin NB, Riedel E, Tustin R 3rd, Murray JB, Peck LM, Khan M, Quinn J, Douglas SD.

Clin Vaccine Immunol. 2012 May;19(5):752-6. doi: 10.1128/CVI.00093-12. Epub 2012 Mar 21.

25.

Substance P-neurokinin-1 receptor interaction upregulates monocyte tissue factor.

Khan MM, Douglas SD, Benton TD.

J Neuroimmunol. 2012 Jan 18;242(1-2):1-8. doi: 10.1016/j.jneuroim.2011.10.012. Epub 2011 Nov 23.

26.

Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner.

Meshki J, Douglas SD, Hu M, Leeman SE, Tuluc F.

PLoS One. 2011;6(9):e25332. doi: 10.1371/journal.pone.0025332. Epub 2011 Sep 23.

27.

A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.

Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, Gonin R, Korelitz J, Douglas SD.

PLoS One. 2011;6(9):e24180. doi: 10.1371/journal.pone.0024180. Epub 2011 Sep 8.

28.

Association between alcohol use and HIV viral load.

Wu ES, Metzger DS, Lynch KG, Douglas SD.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):e129-30. doi: 10.1097/QAI.0b013e31820dc1c8. No abstract available.

29.

Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.

Douglas SD, Leeman SE.

Ann N Y Acad Sci. 2011 Jan;1217:83-95. doi: 10.1111/j.1749-6632.2010.05826.x. Epub 2010 Nov 22. Review.

30.

Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.

Manak MM, Moshkoff DA, Nguyen LT, Meshki J, Tebas P, Tuluc F, Douglas SD.

AIDS. 2010 Nov 27;24(18):2789-96. doi: 10.1097/QAD.0b013e3283405c33.

31.

Immune suppression and immune activation in depression.

Blume J, Douglas SD, Evans DL.

Brain Behav Immun. 2011 Feb;25(2):221-9. doi: 10.1016/j.bbi.2010.10.008. Epub 2010 Oct 16. Review.

32.

Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication.

Benton T, Lynch K, Dubé B, Gettes DR, Tustin NB, Ping Lai J, Metzger DS, Blume J, Douglas SD, Evans DL.

Psychosom Med. 2010 Nov;72(9):925-32. doi: 10.1097/PSY.0b013e3181f883ce. Epub 2010 Oct 14.

33.

Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor.

Monaco-Shawver L, Schwartz L, Tuluc F, Guo CJ, Lai JP, Gunnam SM, Kilpatrick LE, Banerjee PP, Douglas SD, Orange JS.

J Leukoc Biol. 2011 Jan;89(1):113-25. doi: 10.1189/jlb.0410200. Epub 2010 Oct 12.

34.

Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS.

Vinet-Oliphant H, Alvarez X, Buza E, Borda JT, Mohan M, Aye PP, Tuluc F, Douglas SD, Lackner AA.

Am J Pathol. 2010 Sep;177(3):1286-97. doi: 10.2353/ajpath.2010.091109. Epub 2010 Jul 29.

35.

Analytical and biological considerations in the measurement of cell-associated CCR5 and CXCR4 mRNA and protein.

Campbell DE, Lai JP, Tustin NB, Riedel E, Tustin R 3rd, Taylor J, Murray J, Douglas SD.

Clin Vaccine Immunol. 2010 Jul;17(7):1148-54. doi: 10.1128/CVI.00533-09. Epub 2010 May 12.

36.

Enhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity.

Fang CY, Reibel DK, Longacre ML, Rosenzweig S, Campbell DE, Douglas SD.

J Altern Complement Med. 2010 May;16(5):531-8. doi: 10.1089/acm.2009.0018.

37.

Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes.

Campbell DE, Tustin NB, Riedel E, Tustin R 3rd, Taylor J, Murray J, Douglas SD.

Clin Vaccine Immunol. 2009 Nov;16(11):1648-53. doi: 10.1128/CVI.00259-09. Epub 2009 Sep 2.

38.

Planning Future Strategies for Domestic and International NeuroAIDS Research, July 24-25, 2008.

Joseph J, Clifford D, Douglas SD, Fox H, Gendelman HE, Gonzalez-Scarano F, Grant I, Major E, McArthur J; NeuroAIDS Research Participants.

J Neuroimmune Pharmacol. 2009 Sep;4(3):283-97. doi: 10.1007/s11481-009-9159-1. Epub 2009 May 20.

39.

Neurokinin 1 receptor isoforms and the control of innate immunity.

Tuluc F, Lai JP, Kilpatrick LE, Evans DL, Douglas SD.

Trends Immunol. 2009 Jun;30(6):271-6. doi: 10.1016/j.it.2009.03.006. Epub 2009 May 7. Review.

PMID:
19427266
40.

Novel method for determination of substance P levels in unextracted human plasma by using acidification.

Campbell DE, Bruckner P, Tustin NB, Tustin R 3rd, Douglas SD.

Clin Vaccine Immunol. 2009 Apr;16(4):594-6. doi: 10.1128/CVI.00406-08. Epub 2009 Feb 4.

41.

Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism.

Meshki J, Douglas SD, Lai JP, Schwartz L, Kilpatrick LE, Tuluc F.

J Biol Chem. 2009 Apr 3;284(14):9280-9. doi: 10.1074/jbc.M808825200. Epub 2009 Jan 28.

43.

Neurokinin-1 receptor expression and function in human macrophages and brain: perspective on the role in HIV neuropathogenesis.

Douglas SD, Lai JP, Tuluc F, Schwartz L, Kilpatrick LE.

Ann N Y Acad Sci. 2008 Nov;1144:90-6. doi: 10.1196/annals.1418.007.

PMID:
19076368
44.

Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R).

Chernova I, Lai JP, Li H, Schwartz L, Tuluc F, Korchak HM, Douglas SD, Kilpatrick LE.

J Leukoc Biol. 2009 Jan;85(1):154-64. doi: 10.1189/jlb.0408260. Epub 2008 Oct 3.

45.

Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor.

Lai JP, Lai S, Tuluc F, Tansky MF, Kilpatrick LE, Leeman SE, Douglas SD.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12605-10. doi: 10.1073/pnas.0806632105. Epub 2008 Aug 19.

46.

Innate immune markers in mothers and fathers of children newly diagnosed with cancer.

Stehl MJ, Kazak AE, Hwang WT, Pai AL, Reilly AF, Douglas SD.

Neuroimmunomodulation. 2008;15(2):102-7. doi: 10.1159/000148192. Epub 2008 Aug 5.

47.

Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages.

Wang X, Douglas SD, Song L, Wang YJ, Ho WZ.

J Neuroimmune Pharmacol. 2008 Dec;3(4):257-64. doi: 10.1007/s11481-008-9117-3. Epub 2008 Jul 25.

48.

Neurokinin-1 receptor mRNA expression differences in brains of HIV-infected individuals.

Douglas SD, Lynch KG, Lai JP.

J Neurol Sci. 2008 Sep 15;272(1-2):174-7. doi: 10.1016/j.jns.2008.04.025. Epub 2008 Jun 24.

49.

Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D; Pediatric AIDS Clinical Trials Group 381 Study Team.

AIDS Patient Care STDS. 2008 Jul;22(7):545-52. doi: 10.1089/apc.2007.0200.

50.

Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia.

Fang CY, Miller SM, Bovbjerg DH, Bergman C, Edelson MI, Rosenblum NG, Bove BA, Godwin AK, Campbell DE, Douglas SD.

Ann Behav Med. 2008 Feb;35(1):87-96. doi: 10.1007/s12160-007-9007-6. Epub 2008 Feb 13.

Supplemental Content

Loading ...
Support Center